GlassScriptPhysician profile
Gabriel U Sims
NPI 1659751279
$2,910.13
in general payments reported to CMS, 2019-2025
21 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $215 · 2023: $509 · 2024: $730 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $343.84 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $340.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $236.98 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.63 | 2025 | Caplyta |
| Corcept Therapeutics | $111.70 | 2025 | Korlym |
| Exact Sciences Corporation | $90.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $78.42 | 2023-2025 | Auvelity, Sunosi |
| Merz North America, INC. | $66.86 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $61.94 | 2025 | Recorlev |
| Fresenius Kabi USA, LLC | $41.44 | 2025 | |
| Inspire Medical Systems, INC. | $35.08 | 2025 | Inspire |
| Sanofi Pasteur INC. | $27.87 | 2023 | |
| Exeltis, USA INC. | $20.21 | 2025 | Slynd |
| Sunovion Pharmaceuticals INC. | $20.20 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.44 | 2021 | |
| Glaxosmithkline, LLC. | $19.07 | 2024 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $16.05 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.71 | 2025 | Voquezna |
| Antares Pharma, INC. | $14.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.